X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10293) 10293
Book Review (1299) 1299
Publication (957) 957
Conference Proceeding (145) 145
Book Chapter (119) 119
Dissertation (96) 96
Government Document (61) 61
Magazine Article (8) 8
Book / eBook (5) 5
Newsletter (3) 3
Reference (2) 2
Trade Publication Article (2) 2
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (6771) 6771
her2 (6658) 6658
humans (6203) 6203
female (4808) 4808
oncology (4697) 4697
breast cancer (4620) 4620
trastuzumab (3059) 3059
cancer (2502) 2502
receptor, erbb-2 - metabolism (2370) 2370
middle aged (2261) 2261
breast neoplasms - pathology (2104) 2104
immunohistochemistry (1914) 1914
aged (1876) 1876
adult (1814) 1814
breast neoplasms - drug therapy (1735) 1735
receptor, erbb-2 - genetics (1634) 1634
breast neoplasms - metabolism (1631) 1631
chemotherapy (1618) 1618
expression (1529) 1529
prognosis (1464) 1464
animals (1404) 1404
therapy (1395) 1395
breast neoplasms - genetics (1356) 1356
cell line, tumor (1227) 1227
breast-cancer (1175) 1175
pathology (1127) 1127
skin and connective tissue diseases (1125) 1125
tumors (1089) 1089
gene amplification (1076) 1076
metastasis (1028) 1028
epidermal growth factor (1027) 1027
mice (1003) 1003
her2/neu (991) 991
survival (970) 970
analysis (956) 956
research (925) 925
male (918) 918
care and treatment (916) 916
carcinoma (911) 911
medicine & public health (905) 905
monoclonal-antibody (881) 881
aged, 80 and over (875) 875
antineoplastic agents - therapeutic use (874) 874
cell biology (809) 809
in-situ hybridization (796) 796
amplification (761) 761
egfr (732) 732
treatment outcome (731) 731
growth-factor receptor (701) 701
antibodies, monoclonal, humanized (693) 693
biochemistry & molecular biology (682) 682
proteins (661) 661
adjuvant chemotherapy (648) 648
genetic aspects (642) 642
erbb-2 protein (638) 638
gene expression (630) 630
receptor (628) 628
antineoplastic combined chemotherapy protocols - therapeutic use (626) 626
overexpression (625) 625
receptor, erbb-2 - analysis (620) 620
article (616) 616
receptor, erbb-2 - antagonists & inhibitors (610) 610
in situ hybridization, fluorescence (603) 603
lapatinib (595) 595
neoplasm staging (595) 595
neoplasms (591) 591
cells (576) 576
gene expression regulation, neoplastic (571) 571
health aspects (559) 559
retrospective studies (558) 558
pharmacology & pharmacy (555) 555
biomarkers, tumor - metabolism (537) 537
gastric cancer (533) 533
antineoplastic agents - pharmacology (526) 526
growth (511) 511
her-2/neu (510) 510
disease-free survival (509) 509
receptor, erbb-2 - biosynthesis (491) 491
breast neoplasms - mortality (488) 488
resistance (484) 484
receptor, erbb-2 - immunology (480) 480
estrogen-receptor (470) 470
cancer research (468) 468
erbb2 (463) 463
antibodies, monoclonal - therapeutic use (454) 454
cancer therapies (454) 454
medicine, research & experimental (453) 453
metastatic breast-cancer (446) 446
apoptosis (445) 445
signal transduction (443) 443
biomarkers, tumor - analysis (438) 438
breast neoplasms - diagnosis (430) 430
genes, erbb-2 (419) 419
phase-ii (413) 413
mutation (411) 411
biomarkers, tumor - genetics (406) 406
kinases (399) 399
oncogene (397) 397
receptors, estrogen - metabolism (396) 396
surgery (396) 396
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10123) 10123
French (170) 170
German (83) 83
Chinese (62) 62
Japanese (58) 58
Spanish (50) 50
Polish (36) 36
Korean (25) 25
Czech (9) 9
Italian (9) 9
Portuguese (7) 7
Russian (7) 7
Hungarian (6) 6
Persian (5) 5
Turkish (5) 5
Slovenian (4) 4
Swedish (3) 3
Bosnian (1) 1
Catalan (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
American Journal of Clinical Pathology, ISSN 0002-9173, 04/2019, Volume 151, Issue 5, pp. 504 - 510
Abstract Objectives Accurate evaluation of human epidermal growth factor receptor 2 (HER2) in breast cancer is critical. Methods HER2 fluorescence in situ... 
Dako | FISH TESTING INCREASE | CLINICAL ONCOLOGY/COLLEGE | aboratory-developed test | IN-SITU HYBRIDIZATION | FDA-approved HER2 test | HER2 positive | HercepTest | MONOCLONAL-ANTIBODY | HER2 discordance | PATHOLOGY | CHEMOTHERAPY | IMPACT | COLLEGE | HER2 | LDT | 2013 AMERICAN SOCIETY | PATHOLOGISTS GUIDELINE RECOMMENDATIONS | IMMUNOHISTOCHEMISTRY
Journal Article
British Journal of Cancer, ISSN 0007-0920, 04/2009, Volume 100, Issue 7, pp. 1061 - 1067
Journal Article
Oncotarget, ISSN 1949-2553, 2018, Volume 9, Issue 11, pp. 9741 - 9750
A targeted therapy is recommended in case of alteration for breast and gastric carcinomas, but miscellaneous other tumor types are altered at low prevalence.... 
ERBB2/HER2 mutation | Personalized medicine | Targeted therapy | ERBB2/HER2 amplification | Trastuzumab
Journal Article
Oncotarget, ISSN 1949-2553, 01/2019, Volume 10, Issue 8, pp. 803 - 804
Journal Article
Cancer, ISSN 0008-543X, 04/2017, Volume 123, Issue 7, pp. 1115 - 1123
Equivocal human epidermal growth factor receptor 2 (HER2) results resemble HER2‐negative cases, not HER2‐amplified cases. Alternative chromosome 17 probes are... 
equivocal human epidermal growth factor receptor 2 (HER2) results | prognostic significance of equivocal human epidermal growth factor receptor 2 (HER2) results | invasive breast cancer | SMS | RARA | alternative chromosome 17 genes in determining human epidermal growth factor receptor 2 (HER2) status | and retinoic acid receptor α | Smith‐Magenis syndrome | genes as alternative chromosome 17 genes | Smith-Magenis syndrome (SMS) and retinoic acid receptor α (RARA) genes as alternative chromosome 17 genes | prognostic significance of equivocal human epidermal | Smith-Magenis syndrome (SMS) and retinoic acid receptor alpha (RARA) genes as alternative chromosome 17 genes | IN-SITU HYBRIDIZATION | 17 COPY NUMBER | CENTROMERE | PATHOLOGICAL COMPLETE RESPONSE | ADJUVANT TRASTUZUMAB | POLYSOMY | AMPLIFICATION | THERAPY | ONCOLOGY | HER2 STATUS | growth factor receptor 2 (HER2) results | AMERICAN-SOCIETY | Immunohistochemistry | Prognosis | Receptor, ErbB-2 - genetics | Humans | Kaplan-Meier Estimate | In Situ Hybridization, Fluorescence | Biomarkers, Tumor | Chromosomes, Human, Pair 17 - genetics | DNA Copy Number Variations | Breast Neoplasms - genetics | Breast Neoplasms - mortality | Female | Breast Neoplasms - diagnosis | Cohort Studies | Usage | Breast cancer | Research | Reflexes | Testing | Enumeration | Copy number | Invasiveness | Genes | Fluorescence | Hazards | Regression analysis | Patients | Survival | ErbB-2 protein | Training | Confidence intervals | Epidermal growth factor | Fluorescence in situ hybridization | Breast | Clinical medicine | Probes | Chromosomes | Retinoic acid | Chromosome 17 | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Histotechnology, ISSN 0147-8885, 09/2014, Volume 37, Issue 3, pp. 90 - 94
Determining human epidermal growth factor receptor 2 (HER2) status in breast cancer patients can be attained by fluorescent in situ hybridization (FISH)... 
HER2 IQFISH pharmDx | assay | FISH validation | HER2 FISH pharmDx | HER2 amplification | Fluorescence in situ hybridization | HER2 IQFISH pharmDx™ assay | HER2 FISH pharmDx™ assay | HER2 IQFISH pharmDx(TM) assay | HER2 FISH pharmDx(TM) assay | CELL BIOLOGY
Journal Article
CANCER SCIENCE, ISSN 1349-7006, 01/2018, Volume 109, pp. 125 - 125
Conference Proceeding
Frontiers in Oncology, ISSN 2234-943X, 2012, Volume 2, pp. 62 - 62
HER2-positive breast cancer accounts for 20-30% of all breast cancers and has the second-poorest prognosis among breast cancer subtypes. The approval of... 
Herceptin | Targeted therapies | Breast cancer | HER2/ERBB2 | Trastuzumab | HER3 | trastuzumab | breast cancer | targeted therapies
Journal Article
CURRENT CANCER DRUG TARGETS, ISSN 1568-0096, 2019, Volume 19, Issue 1, pp. 65 - 73
Background: Expression of human epidermal growth factor receptor type 2 (HER2) in head and neck squamous cell carcinoma (HNSCC) cell line HN5 can be employed... 
PROTEIN | MOLECULE | CANCER | HER2 receptor | HN5 cell | specific targeting | DELIVERY | AGENT | IMPACT | CISPLATIN | ONCOLOGY | HER2 EXPRESSION | Head and neck cancer | idarubicin-Z(HER2) affibody conjugate | BINDING | LIPOSOMES
Journal Article
JOURNAL OF NUCLEAR MEDICINE, ISSN 0161-5505, 10/2016, Volume 57, Issue 10, pp. 1523 - 1528
Our objective was to determine whether imaging with a human epidermal growth factor receptor 2 (HER2)-targeted PET tracer can detect HER2-positive metastases... 
ANTIBODIES | FACTOR RECEPTOR 2 | molecular imaging | TUMORS | oncology | CHEMOTHERAPY | trastuzumab | IMPACT | AMPLIFICATION | PET/CT | HER2 EXPRESSION | HER2 | breast | CARCINOMA | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | PLUS
Journal Article
Frontiers in Oncology, ISSN 2234-943X, 2013, Volume 3, pp. 129 - 129
HER2 overexpression and anti-HER2 agents represent probably the best story of success of individualized therapy in breast cancer. Due to the important... 
Therapy | CEP17 amplification | Test | Diagnosis | HER2 | HER2 mutations | Truncated HER2 | diagnosis | test | therapy | truncated HER2
Journal Article
Journal Article
Journal Article
Journal Article